16 September 2019 - Lenvima (lenvatinib), a new liver cancer drug that arrived in a decade after Nexavar (sorafenib), is to enjoy insurance benefit in the first-line treatment of hepatocellular carcinoma, the health authorities said. 

Eisai Korea released Lenvima in Korea about a year ago.

The Health Insurance Review and Assessment Service said Monday that it would expand the reimbursement of Lenvima in the first-line treatment for patients with advanced hepatocellular carcinoma who cannot undergo surgery or topical treatment. If the pharmaceutical industry does not have any different opinion until Friday this week, the expanded reimbursement will start from 1 October.

Read Korea Biomedical Review article